98%
921
2 minutes
20
Background: Mass drug administration (MDA) with azithromycin (AZ) is being considered as a strategy to promote child survival in sub-Saharan Africa, but the mechanism by which AZ reduces mortality is unclear. To better understand the nature and extent of protection provided by AZ, we explored the profile of protection by time since administration, using data from a household-randomized, placebo-controlled trial in Burkina Faso and Mali.
Methods: Between 2014 and 2016, 30 977 children aged 3-59 months received seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine and either AZ or placebo monthly, on 4 occasions each year. Poisson regression with gamma-distributed random effects, accounting for the household randomization and within-individual clustering of illness episodes, was used to compare incidence of prespecified outcomes between SMC+AZ versus SMC+placebo groups in fixed time strata post-treatment. The likelihood ratio test was used to assess evidence for a time-treatment group interaction.
Results: Relative to SMC+placebo, there was no evidence of protection from SMC+AZ against hospital admissions and deaths. Additional protection from SMC+AZ against malaria was confined to the first 2 weeks post-administration (protective efficacy (PE): 24.2% [95% CI: 17.8%, 30.1%]). Gastroenteritis and pneumonia were reduced by 29.9% [21.7; 37.3%], and 34.3% [14.9; 49.3%], respectively, in the first 2 weeks postadministration. Protection against nonmalaria fevers with a skin condition persisted up to 28 days: PE: 46.3% [35.1; 55.6%].
Conclusions: The benefits of AZ-MDA are broad-ranging but short-lived. To maximize impact, timing of AZ-MDA must address the challenge of targeting asynchronous morbidity and mortality peaks from different causes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492219 | PMC |
http://dx.doi.org/10.1093/cid/ciaa1905 | DOI Listing |
Commun Med (Lond)
September 2025
Department of Microbiology and Immunology, Bio21 Institute and The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Background: Mixed-species, mixed-strain plasmodia infections are known to occur in humans in malaria endemic areas. It may be surprising that to date, the extent of this complexity has not been systematically explored in high-burden countries of sub-Saharan Africa, especially in the reservoir of asymptomatic infections in all ages, which sustains transmission.
Methods: Here we take a metagenomic lens to these infections by sampling variable blood volumes from 188 afebrile residents living in high, seasonal transmission in Northern Sahelian Ghana.
Vaccine
September 2025
Centre for Quantitative Medicine, Duke-NUS Medical School, 20 College Road, 169856, Singapore; Signature Programme in Health Services & Systems Research, Duke-NUS Medical School, 8 College Road, 169857, Singapore; Tampere Center for Child, Adolescent and Maternal Health Research, Tampere University,
The Cox model and its extensions assuming proportional hazards is widely used to estimate vaccine efficacy (VE). However, when VE wanes over time, estimates can become sensitive to study duration and timing of vaccine delivery relative to disease seasonality, and may be biased due to sample attrition. Additionally, estimates of vaccine impact such as number of cases averted (NCA) are sensitive to background disease incidence and timing of vaccine delivery.
View Article and Find Full Text PDFCureus
July 2025
Department of General Medicine, Mufti Mehmood Memorial Teaching Hospital, Medical Teaching Institute, Dera Ismail Khan, PAK.
Background Dengue fever significantly burdens healthcare systems, particularly in resource-limited settings such as Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan. Mufti Mehmood Memorial Teaching Hospital, the designated Dengue Isolation Unit in the region, continues to receive a steady influx of patients. This study analyzed the epidemiological profile of dengue cases admitted to the hospital to support public health planning and guide resource allocation.
View Article and Find Full Text PDFmedRxiv
August 2025
Department of Microbiology and Immunology, Bio21 Institute and Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Current interventions targeting malaria control in sub-Saharan Africa (SSA) are focused on , the most prevalent species infecting humans. Despite renewed efforts for malaria elimination in SSA, little attention has been paid to the neglected parasites and spp. and the impact of interventions like long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS) with non-pyrethroid insecticides, and/or seasonal malaria chemoprevention (SMC) on these minor spp.
View Article and Find Full Text PDFMalar J
September 2025
Institut de Recherche en Sciences de La Santé (IRSS), ClinicalResearch Unit of Nanoro (CRUN), Nanoro, Burkina Faso.
Background: Seasonal Malaria Chemoprevention (SMC) has been adopted since 2014 in Burkina Faso to reduce malaria burden in children under 5 years. However, the intervention's expected potential has not yet been achieved in real-life conditions, suggesting other factors may influence its effectiveness. Asymptomatic carriers, including patent and sub-patent Plasmodium falciparum infections in household members seems to be a potential factor maintaining the high malaria burden in children under SMC coverage.
View Article and Find Full Text PDF